San Diego, CA — August 28, 2024 — BTS Research, a leading contract research organization specializing in preclinical research services, is proud to announce the successful completion of its USDA inspection with zero findings. The inspection was triggered by the recent acquisition of BTS Research by PharmaLegacy,

The inspection, which took place August 27, 2024, underscores BTS Research's commitment to maintaining the highest standards of quality and compliance in its operations. The USDA's thorough assessment found no areas of concern, reflecting BTS Research's dedication to excellence and regulatory adherence. Despite the minor recommendations from the USDA, BTS Research promptly addressed these suggestions to further strengthen its operational efficiency and compliance framework.

"We remain focused on delivering exceptional service and maintaining regulatory excellence," said Usama Abunadi, President & CEO of BTS Research. "This accomplishment reflects our team's dedication and expertise in providing reliable and high-quality research solutions."

In addition to the successful inspection, BTS Research recently announced its acquisition by PharmaLegacy, a strategic move aimed at enhancing capabilities and expanding service offerings to better serve our clients in the pharmaceutical and biotechnology industries.

For more information about BTS Research and its comprehensive range of preclinical research services, please visit https://btsresearch.com/.